Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T02677
|
||||
| Former ID |
TTDC00273
|
||||
| Target Name |
Baculoviral IAP repeat-containing protein 5
|
||||
| Gene Name |
BIRC5
|
||||
| Synonyms |
Apoptosis inhibitor 4; Apoptosis inhibitor survivin; Survivin; BIRC5
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
| Non-small cell lung cancer [ICD10: C33-C34] | |||||
| Ovarian cancer [ICD9: 183; ICD10: C56] | |||||
| Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
| Function |
May play a role in neoplasia. May counteract a default induction of apoptosis in g2/m phase. Interacts with tubulin. Inhibitor of caspase-3 and caspase-7.
|
||||
| BioChemical Class |
Inhibitor of apoptosis
|
||||
| Target Validation |
T02677
|
||||
| UniProt ID | |||||
| Sequence |
MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFC
FKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNK KKEFEETAKKVRRAIEQLAAMD |
||||
| Drugs and Mode of Action | |||||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Hippo signaling pathway | ||||
| Hepatitis B | |||||
| Pathways in cancer | |||||
| Colorectal cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| Pathway Interaction Database | Aurora B signaling | ||||
| Validated targets of C-MYC transcriptional activation | |||||
| FOXM1 transcription factor network | |||||
| Aurora A signaling | |||||
| Reactome | Separation of Sister Chromatids | ||||
| Resolution of Sister Chromatid Cohesion | |||||
| RHO GTPases Activate Formins | |||||
| Mitotic Prometaphase | |||||
| WikiPathways | IL-4 Signaling Pathway | ||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Mitotic Metaphase and Anaphase | |||||
| Mitotic Prometaphase | |||||
| Apoptosis | |||||
| Interleukin-11 Signaling Pathway | |||||
| Apoptosis Modulation and Signaling | |||||
| References | |||||
| Ref 522696 | ClinicalTrials.gov (NCT00923312) Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.